Boehringer Ingelheim International Gmbh

Vifor (international) Ag

Vifor Ag

John Scott

Georg Dahmann

Matthias Hoffmann

Clive Mccarthy

Wilm Buhr

Christopher John Yarnold

Stefan Reim

Cristina Lecci

Michael Burgert

Franz Dürrenberger

Susanna Burckhardt

Aris Kalogerakis

Jasna Klicic

Jon Shepherd

Susan Boyce

Paula Pena

Richard Jarjes-Pike

Vania Manolova

Stephen East

Spencer Charles R Napier

Gerhard Schaenzle

Edward Walker

Christian Gnamm

Daniel Bischoff

Daniel Robert Fandrick

Stefan Ludwig Michael Wollin

Serge Convers-Reignier

Frederic Jacques Marlin

David James Lamb

Jennifer L Swantek Fitzgerald

Karen Parrish

Martin Thomas Fleck

Dennis Fiegen

Jasna Klicic Badoux

Stephen Peter East

Spencer Napier

Stefan Ludwig Wollin

Serge Gaston Convers-Reignier

The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.

Ferroportin inhibitors

The invention relates to new substituted heteroaryls of formula 1 wherein

Heteroaryl SYK inhibitors

The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis. 

The invention relates to novel compounds of the general formula (A-I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula (AA) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis. 

The invention relates to new substituted heteroaryls of formula 1 or of formula 1' wherein A is either N or CH,wherein Ris selected from the group consisting of &#x2014;C-alkyl, &#x2014;C-haloalkyl, F, Br, Cl,wherein Y is selected from &#x2014;O&#x2014; or &#x2014;CH&#x2014;,and wherein Ris defined as in claim, and the pharmaceutically acceptable salts thereof,and the use of these aforementioned compounds for the treatment of diseases such as asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.

Pyrazolyl-substituted heteroaryls and their use as medicaments

The invention relates to new substituted heteroaryls of formula (1), wherein A is selected from the group consisting of N and CH, D is CH, E is selected from the group consisting of C and N, T is C, G is selected from the group consisting of C and N, and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all single and double bonds of ring 1 are arranged in such a way that they all form together with ring 2 an aromatic ring system, and wherein R, M and Rare defined according to claim, and to the above compounds for the treatment of a disease selected from the group consisting of asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis. 

Heteroaryl Syk inhibitors

The invention relates to new substituted heteroaryls of formula 1 or of formula 

Disclosed are substituted quinolines of formula 1 whereinRand Rare defined herein, the processing of making and using the same.

Substituted quinolines and their use as medicaments

The invention relates to new substituted pyridinyl-pyrimidines of formula 

Substituted pyridinyl-pyrimidines and their use as medicaments

Growing community of inventors

Abingdon, United Kingdom

John Scott